Yoshikatsu Kanai

List of Publications by Year
in descending order

150 papers	15,566 citations	26567 56 h-index	17055 122 g-index
154 all docs	154 docs citations	154 times ranked	11739 citing authors

#	Article	IF	Citations
1	Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. , 2022, 230, 107964.		78
2	Simple But Efficacious Enrichment of Integral Membrane Proteins and Their Interactions for In-Depth Membrane Proteomics. Molecular and Cellular Proteomics, 2022, 21, 100206.	2.5	20
3	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Scientific Reports, 2022, 12, 2742.	1.6	13
4	Tmem174, a regulator of phosphate transporter prevents hyperphosphatemia. Scientific Reports, 2022, 12, 6353.	1.6	3
5	Functional coupling of organic anion transporter OAT10 (SLC22A13) and monocarboxylate transporter MCT1 (SLC16A1) influencing the transport function of OAT10. Journal of Pharmacological Sciences, 2022, , .	1.1	3
6	Structural changes induced by ligand binding drastically increase the thermostability of the Ser/Thr protein kinase TpkD from ThermusÂthermophilus HB8. FEBS Letters, 2021, 595, 264-274.	1.3	3
7	Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Translational Oncology, 2021, 14, 100915.	1.7	27
8	Î±â€Emitting cancer therapy using ²¹¹Atâ€AAMT targeting LAT1. Cancer Science, 2021, 112, 1132-1140.	1.7	31
9	Individual dosimetry system for targeted alpha therapy based on PHITS coupled with microdosimetric kinetic model. EJNMMI Physics, 2021, 8, 4.	1.3	19
10	Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms. In Vivo, 2021, 35, 2425-2432.	0.6	6
11	Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor. Cancer Science, 2021, 112, 3871-3883.	1.7	19
12	Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor. Cancer Science, 2021, 112, 871-883.	1.7	15
13	Studies on the Incompatibility between Bulbus fritillariae and Radix aconiti praeparata Based on the P-gp. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-11.	0.5	0
14	LAT1â€specific inhibitor is effective against T cellâ€mediated allergic skin inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 463-467.	2.7	16
15	Interaction of Halogenated Tyrosine/Phenylalanine Derivatives with Organic Anion Transporter 1 in the Renal Handling of Tumor Imaging Probes. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 451-462.	1.3	7
16	Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation. Journal of Experimental and Clinical Cancer Research, 2020, 39, 266.	3.5	36
17	Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. Pflugers Archiv European Journal of Physiology, 2020, 472, 1177-1206.	1.3	53
18	Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Scientific Reports, 2020, 10, 1292.	1.6	35

#	Article	IF	Citations
19	A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy. PLoS ONE, 2020, 15, e0241869.	1.1	12
20	Targeted alpha therapy using astatine (211At)-labeled phenylalanine: A preclinical study in glioma bearing mice. Oncotarget, 2020, 11, 1388-1398.	0.8	30
21	Evaluation of D-isomer of F-FBPA for oncology PET focusing on the differentiation of glioma and inflammation. Asia Oceania Journal of Nuclear Medicine and Biology, 2020, 8, 102-108.	0.1	2
22	Title is missing!. , 2020, 15, e0241869.		0
23	Title is missing!. , 2020, 15, e0241869.		0
24	Title is missing!. , 2020, 15, e0241869.		0
25	Title is missing!. , 2020, 15, e0241869.		0
26	Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc. Nature Structural and Molecular Biology, 2019, 26, 510-517.	3.6	110
27	CYP450s-Activity Relations of Celastrol to Interact with Triptolide Reveal the Reasons of Hepatotoxicity of Tripterygium wilfordii. Molecules, 2019, 24, 2162.	1.7	45
28	Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer. Anticancer Research, 2019, 39, 2535-2543.	0.5	21
29	Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter. Journal of Pharmacological Sciences, 2019, 139, 215-222.	1.1	21
30	Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2. Annals of Nuclear Medicine, 2019, 33, 394-403.	1.2	10
31	Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Human Pathology, 2019, 84, 142-149.	1.1	26
32	Developing selective L-Amino Acid Transport 1 (LAT1) inhibitors: A Structure-Activity Relationship overview. Medical Research Archives, 2019, 7, .	0.1	4
33	Development of anti-tumor drugs targeting amino acid transporters in cancers. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2019, 92, JKG-02.	0.0	0
34	Comparative phosphoproteomics between non-competitive and competitive inhibitions of L-type amino acid transporter 1 in cancer cells.. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2019, 92, 1-P-106.	0.0	0
35	Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 141-153.	1.1	45
36	Amino acid transporters revisited: New views in health and disease. Trends in Biochemical Sciences, 2018, 43, 752-789.	3.7	308

#	Article	IF	Citations
37	Negative regulation of amino acid signaling by MAPK-regulated 4F2hc/Girdin complex. PLoS Biology, 2018, 16, e2005090.	2.6	11
38	Comprehensive protein analysis of the transport system in a connective tissue of the inner ear. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-145.	0.0	0
39	Phosphoproteome analysis reveals novel cellular responses affect by inhibition of LAT1, a cancer type amino acid transporter. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-46.	0.0	0
40	Structure activity relations of aromatic amino acid derivatives to interact with organic anion transporter OAT1 reveal critical moieties for renal accumulation of tumor imaging probes. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-8-40.	0.0	0
41	L-type amino acid transporter 1 (LAT1) in endothelial cells of tumor vessels contributes to tumor angiogenesis. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-30.	0.0	0
42	BPA-dipeptides, novel boron delivery agents for boron neutron capture therapy, are transported by oligopeptide transporter. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-32.	0.0	0
43	Combination of amino acids necessary and sufficient for the optimal activation of mTORC1. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-6-13.	0.0	0
44	Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). Journal of Pharmacological Sciences, 2017, 133, 96-102.	1.1	60
45	Essential Roles of L-Type Amino Acid Transporter 1 in Syncytiotrophoblast Development by Presenting Fusogenic 4F2hc. Molecular and Cellular Biology, 2017, 37, .	1.1	43
46	Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans. Pharmaceutical Research, 2017, 34, 1233-1243.	1.7	8
47	Impairment of the carnitine/organic cation transporter 1â€“ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease. Kidney International, 2017, 92, 1356-1369.	2.6	39
48	Slc3a2 Mediates Branched-Chain Amino-Acid-Dependent Maintenance of Regulatory T Cells. Cell Reports, 2017, 21, 1824-1838.	2.9	95
49	18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 321-331.	3.3	56
50	Ultrastructural immunohistochemical study of L-type amino acid transporter 1â€“4F2 heavy chain in tumor microvasculatures of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced rat bladder carcinoma. Journal of Electron Microscopy, 2017, 66, 198-203.	0.9	3
51	Ratiometric fluorescence imaging of cell surface pH by poly(ethylene glycol)-phospholipid conjugated with fluorescein isothiocyanate. Scientific Reports, 2017, 7, 17484.	1.6	34
52	Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer. Anticancer Research, 2017, 37, 631-636.	0.5	9
53	Clinical Significance and Phenotype of MTA1 Expression in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2017, 37, 4147-4155.	0.5	9
54	Expression of a human NPT1/SLC17A1 missense variant which increases urate export. Nucleosides, Nucleotides and Nucleic Acids, 2016, 35, 536-542.	0.4	11

#	Article	IF	Citations
55	Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder. Cell, 2016, 167, 1481-1494.e18.	13.5	265
56	Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 94-102.	1.3	58
57	Specific transport of 3â€fluoroâ€<scp>l</scp>â€Î±â€methylâ€tyrosine by <scp>LAT</scp>1 explains its specificity to malignant tumors in imaging. Cancer Science, 2016, 107, 347-352.	1.7	35
58	Regulation of amino acid transporter trafficking by mTORC1Âin primary human trophoblast cells is mediated by the ubiquitin ligase Nedd4-2. Clinical Science, 2016, 130, 499-512.	1.8	76
59	Efficacy of system <scp>l</scp> amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Science, 2016, 107, 1499-1505.	1.7	40
60	Transport of 3-fluoro-l-Î±-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [18F]FAMT positron emission tomography. Journal of Pharmacological Sciences, 2016, 130, 101-109.	1.1	15
61	Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. Journal of Surgical Oncology, 2016, 113, 381-389.	0.8	38
62	Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 775-780.	3.3	72
63	Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells. Journal of Urology, 2016, 195, 1588-1597.	0.2	57
64	Structureâ€“activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling. Amino Acids, 2016, 48, 1045-1058.	1.2	51
65	Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Annals of the Rheumatic Diseases, 2016, 75, 652-659.	0.5	144
66	Boronophenylalanine, a boron delivery agent forÂboron neutron capture therapy, is transported byÂ<scp>ATB</scp>^{0,+}, <scp>LAT</scp>1 and <scp>LAT</scp>2. Cancer Science, 2015, 106, 279-286.	1.7	109
67	Functional identification of SLC43A3 as an equilibrative nucleobase transporter involved in purine salvage in mammals. Scientific Reports, 2015, 5, 15057.	1.6	47
68	Increased placental nutrient transport in a novel mouse model of maternal obesity with fetal overgrowth. Obesity, 2015, 23, 1663-1670.	1.5	95
69	Expression and functional characterisation of System L amino acid transporters in the human term placenta. Reproductive Biology and Endocrinology, 2015, 13, 57.	1.4	59
70	CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma. Head and Neck, 2015, 37, 1569-1574.	0.9	22
71	Expression of amino acid transporters (<scp>LAT1</scp>, <scp>ASCT2</scp> and <scp>xCT</scp>) as clinical significance in hepatocellular carcinoma. Hepatology Research, 2015, 45, 1014-1022.	1.8	51
72	Molecular architecture of the stria vascularis membrane transport system, which is essential for physiological functions of the mammalian cochlea. European Journal of Neuroscience, 2015, 42, 1984-2002.	1.2	33

#	Article	IF	Citations
73	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Research, 2015, 25, 399-405.	0.6	52
74	Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma. Pathology and Oncology Research, 2015, 21, 1175-1181.	0.9	34
75	Development of a Widely Usable Amino Acid Tracer: ⁷⁶Br-Î±-Methyl-Phenylalanine for Tumor PET Imaging. Journal of Nuclear Medicine, 2015, 56, 791-797.	2.8	20
76	Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in tongue cancer.. Journal of Clinical Oncology, 2015, 33, e22204-e22204.	0.8	0
77	Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer. American Journal of Translational Research (discontinued), 2015, 7, 356-63.	0.0	15
78	Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. American Journal of Translational Research (discontinued), 2015, 7, 1126-39.	0.0	23
79	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. American Journal of Translational Research (discontinued), 2015, 7, 1161-71.	0.0	23
80	Expression of Lâ€type amino acid transporter 1 (<scp>LAT</scp>1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Science, 2014, 105, 1496-1502.	1.7	54
81	JPH203, an L-Type Amino Acid Transporter 1â€“Selective Compound, Induces Apoptosis of YD-38 Human Oral Cancer Cells. Journal of Pharmacological Sciences, 2014, 124, 208-217.	1.1	62
82	Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma. Pathology and Oncology Research, 2013, 19, 649-656.	0.9	16
83	Diagnostic usefulness of 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1692-1700.	3.3	38
84	Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells. Journal of Physiology, 2013, 591, 609-625.	1.3	152
85	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Molecular Aspects of Medicine, 2013, 34, 108-120.	2.7	255
86	The small SLC43 family: Facilitator system l amino acid transporters and the orphan EEG1. Molecular Aspects of Medicine, 2013, 34, 638-645.	2.7	66
87	The SLC3 and SLC7 families of amino acid transporters. Molecular Aspects of Medicine, 2013, 34, 139-158.	2.7	516
88	Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer, 2013, 13, 482.	1.1	81
89	L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer. Molecular and Clinical Oncology, 2013, 1, 274-280.	0.4	44
90	Transport of 3-Fluoro-l-Î±-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET. Journal of Nuclear Medicine, 2012, 53, 1253-1261.	2.8	120

#	Article	IF	Citations
91	Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With ^|^alpha;-Alkyl Moieties. Journal of Pharmacological Sciences, 2012, 119, 368-380.	1.1	67
92	Linkage of N-cadherin to multiple cytoskeletal elements revealed by a proteomic approach in hippocampal neurons. Neurochemistry International, 2012, 61, 240-250.	1.9	18
93	NRFL-1, the C. elegans NHERF Orthologue, Interacts with Amino Acid Transporter 6 (AAT-6) for Age-Dependent Maintenance of AAT-6 on the Membrane. PLoS ONE, 2012, 7, e43050.	1.1	11
94	Correlation of Lâ€type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Science, 2012, 103, 382-389.	1.7	152
95	Maternal Protein Restriction in the Rat Inhibits Placental Insulin, mTOR, and STAT3 Signaling and Down-Regulates Placental Amino Acid Transporters. Endocrinology, 2011, 152, 1119-1129.	1.4	146
96	LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. American Journal of Translational Research (discontinued), 2011, 3, 468-78.	0.0	51
97	Inhibition of L-Type Amino Acid Transporter Modulates the Expression of Cell Cycle Regulatory Factors in KB Oral Cancer Cells. Biological and Pharmaceutical Bulletin, 2010, 33, 1117-1121.	0.6	25
98	<scp>l</scp>â€type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Science, 2010, 101, 173-179.	1.7	216
99	Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Research, 2010, 30, 4819-28.	0.5	95
100	Amino Acid Transporter LAT3 Is Required for Podocyte Development and Function. Journal of the American Society of Nephrology: JASN, 2009, 20, 1586-1596.	3.0	34
101	¹⁸F-FMT Uptake Seen Within Primary Cancer on PET Helps Predict Outcome of Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2009, 50, 1770-1776.	2.8	47
102	Lâ€type aminoâ€acid transporter 1 as a novel biomarker for highâ€grade malignancy in prostate cancer. Pathology International, 2009, 59, 7-18.	0.6	204
103	Evaluation of thoracic tumors with ¹⁸Fâ€FMT and ¹⁸Fâ€FDG PETâ€CT: A clinicopathological study. International Journal of Cancer, 2009, 124, 1152-1160.	2.3	36
104	<scp>L</scp>â€type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. Journal of Surgical Oncology, 2009, 99, 433-438.	0.8	39
105	Lâ€type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I nonâ€small cell lung cancer. Histopathology, 2009, 54, 804-813.	1.6	49
106	CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases. Annals of Surgical Oncology, 2009, 16, 3473-3481.	0.7	65
107	System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Letters, 2009, 276, 95-101.	3.2	60
108	Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer, 2009, 66, 120-126.	0.9	65

#	Article	IF	Citations
109	Significance of System L Amino Acid Transporter 1 (LAT-1) and 4F2 Heavy Chain (4F2hc) Expression in Human Developing Intestines. Acta Histochemica Et Cytochemica, 2009, 42, 73-81.	0.8	7
110	A novel role of the C-terminus of b0,+AT in the ERâ€“Golgi trafficking of the rBATâ€“b0,+AT heterodimeric amino acid transporter. Biochemical Journal, 2009, 417, 441-448.	1.7	20
111	Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathology Research and Practice, 2008, 204, 553-561.	1.0	53
112	<scp>l</scp>â€type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Science, 2008, 99, 2380-2386.	1.7	126
113	BCH, an Inhibitor of System L Amino Acid Transporters, Induces Apoptosis in Cancer Cells. Biological and Pharmaceutical Bulletin, 2008, 31, 1096-1100.	0.6	115
114	Establishment and Characterization of Mammalian Cell Lines Stably Expressing Human L-Type Amino Acid Transporters. Journal of Pharmacological Sciences, 2008, 108, 505-516.	1.1	63
115	ENHANCED TUMOR GROWTH ELICITED BY L-TYPE AMINO ACID TRANSPORTER 1 IN HUMAN MALIGNANT GLIOMA CELLS. Neurosurgery, 2008, 62, 493-504.	0.6	118
116	Expression of Amino Acid Transporters in Cancers and Their Application to Cancer Diagnosis and Therapuitics. Membrane, 2008, 33, 108-117.	0.0	1
117	Characterization of amino acid transport system L in HTB-41 human salivary gland epidermoid carcinoma cells. Anticancer Research, 2008, 28, 2649-55.	0.5	8
118	Fluorine-18-Î±-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study. Clinical Cancer Research, 2007, 13, 6369-6378.	3.2	99
119	Protein Characterization of Na+-Independent System L Amino Acid Transporter 3 in Mice. American Journal of Pathology, 2007, 170, 888-898.	1.9	39
120	Gene expression profiles in t24 human bladder carcinoma cells by inhibiting an l-type amino acid transporter, lat1. Archives of Pharmacal Research, 2007, 30, 444-452.	2.7	12
121	Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 681-690.	1.4	68
122	Organic Anion Transporter Family: Current Knowledge. Journal of Pharmacological Sciences, 2006, 100, 411-426.	1.1	186
123	L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. International Journal of Cancer, 2006, 119, 484-492.	2.3	211
124	The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Research, 2006, 26, 2943-8.	0.5	36
125	Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule. Archives of Pharmacal Research, 2005, 28, 421-432.	2.7	39
126	Lysophosphatidylcholine Enhances Cytokine Production of Endothelial Cells via Induction of L-Type Amino Acid Transporter 1 and Cell Surface Antigen 4F2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1640-1645.	1.1	48

#	Article	IF	Citations
127	The ancillary proteins of HATs: SLC3 family of amino acid transporters. Pflugers Archiv European Journal of Physiology, 2004, 447, 490-494.	1.3	140
128	CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Archiv European Journal of Physiology, 2004, 447, 532-542.	1.3	587
129	Expression and functional characterization of the system l amino acid transporter in KB human oral epidermoid carcinoma cells. Cancer Letters, 2004, 205, 215-226.	3.2	26
130	Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusor lesions. Anticancer Research, 2004, 24, 1671-5.	0.5	44
131	Identification of a Novel System L Amino Acid Transporter Structurally Distinct from Heterodimeric Amino Acid Transporters. Journal of Biological Chemistry, 2003, 278, 43838-43845.	1.6	203
132	Identification of a Novel Na+-independent Acidic Amino Acid Transporter with Structural Similarity to the Member of a Heterodimeric Amino Acid Transporter Family Associated with Unknown Heavy Chains. Journal of Biological Chemistry, 2002, 277, 21017-21026.	1.6	63
133	Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition. Molecular Pharmacology, 2002, 61, 729-737.	1.0	361
134	Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1565, 112-122.	1.4	127
135	Molecular identification of a renal urateâ€“anion exchanger that regulates blood urate levels. Nature, 2002, 417, 447-452.	13.7	1,270
136	Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1514, 291-302.	1.4	604
137	Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation. Biochemical Journal, 2001, 358, 693-704.	1.7	60
138	Expression Cloning of a Na+-independent Aromatic Amino Acid Transporter with Structural Similarity to H+/Monocarboxylate Transporters. Journal of Biological Chemistry, 2001, 276, 17221-17228.	1.6	211
139	Identification and Characterization of a Novel Member of the Heterodimeric Amino Acid Transporter Family Presumed to be Associated with an Unknown Heavy Chain. Journal of Biological Chemistry, 2001, 276, 49390-49399.	1.6	69
140	Heterodimeric Amino Acid Transporters: Molecular Biology and Pathological and Pharmacological Relevance. Current Drug Metabolism, 2001, 2, 339-354.	0.7	133
141	Expression of a system L neutral amino acid transporter at the bloodâ€“brain barrier. NeuroReport, 2000, 11, 3507-3511.	0.6	128
142	The 4F2hc/LAT1 complex transports l-DOPA across the bloodâ€“brain barrier. Brain Research, 2000, 879, 115-121.	1.1	253
143	Identification of an Amino Acid Transporter Associated with the Cystinuria-related Type II Membrane Glycoprotein. Journal of Biological Chemistry, 1999, 274, 28845-28848.	1.6	158
144	Identification and Functional Characterization of a Na+-independent Neutral Amino Acid Transporter with Broad Substrate Selectivity. Journal of Biological Chemistry, 1999, 274, 19745-19751.	1.6	443

#	Article	IF	Citations
145	Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98). Journal of Biological Chemistry, 1998, 273, 23629-23632.	1.6	945
146	Expression Cloning and Characterization of a Novel Multispecific Organic Anion Transporter. Journal of Biological Chemistry, 1997, 272, 18526-18529.	1.6	553
147	Localization of the high-affinity glutamate transporter EAAC1 in rat kidney. American Journal of Physiology - Renal Physiology, 1997, 273, F1023-F1029.	1.3	30
148	Molecular Characteristics of Na+-coupled Glucose Transporters in Adult and Embryonic Rat Kidney. Journal of Biological Chemistry, 1995, 270, 29365-29371.	1.6	176
149	Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature, 1994, 368, 563-566.	13.7	838
150	Primary structure and functional characterization of a high-affinity glutamate transporter. Nature, 1992, 360, 467-471.	13.7	1,276